Skip to content

Investigation of the Safety of a Disposable Powered Articulating Endoscopic Linear Cutter Stapler & Reloads technology (Lunar®U) in bariatric surgery

Investigation of the Safety of a Disposable Powered Articulating Endoscopic Linear Cutter Stapler & Reloads technology (Lunar®U) in bariatric surgery - PSTBS Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00034281
Enrollment
200
Registered
2024-05-23
Start date
2024-06-03
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E66.0

Interventions

Group 1: Study group Sleeve gastrectomy using Disposable Powered Articulating Endoscopic Linear Cutter Stapler & Reloads technology with flat deck 50% of cases Group 2: Study group Sleeve gastrectom

Sponsors

Rivolution GmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Written informed consent - Age > 18 years - BMI Grad II (= 35(kg/m²) and Grad III (=40 kg/m²) - Patient considered for Sleeve Gastrectomy according to national and international guideline and according to the standards of the individual bariatric center - Patients with a BMI = 35 kg/m2 with one or more obesity-associated comorbidities such as type 2 diabetes mellitus, coronary heart disease, heart failure, hyperlipidemia, arterial hypertension, obstructive sleep apnea syndrome (OSAS), obesity hypoventilation syndrome, Pickwick syndrome, non-alcoholic Fatty liver disease (NAFLD) or non-alcoholic steaoto- hepatitis (NASH), pseudotumor cerebri, gastroesophageal reflux disease (GERD), asthma, chronic venous insufficiency, urinary incontinence, immobilizing joint disease, fertility impairment, or polycystic ovary syndrome, bariatric surgery - A primary indication in the sense of metabolic surgery can be made with a BMI = 40 kg/m² and coexisting type 2 diabetes mellitus if the improvement of the glycemic metabolism is more important than weight reduction as the treatment goal.

Exclusion criteria

Exclusion criteria: The following exclusion criteria will be considered: • Pregnancy, or the non-exclusion of pregnancy (for women of childbearing potential) * • Previous gastric surgery • Known Coagulopathy and/or Anticoagulation therapy • Esophageal Varices, • Liver cirrhosis • Lack of legal capacity • Vulnerable persons according to the law • Participating in another study

Design outcomes

Primary

MeasureTime frame
Frequency and severity of intra- and postoperative bleeding and staple line leakage in both groups

Secondary

MeasureTime frame
- 5-point Likert-type scale for bleeding severity: 1: No bleeding [yes/no], 2: Minimal bleeding [yes/no], 3: Moderate bleeding [yes/no] 4: Excessive bleeding [yes/no], 5: Profuse bleeding [yes/no] - Usability ->> firing force, firing speed, general handling surgeon satisfaction - Number of FulGrip Reloads used in group SG - Number of Flat Deck Reloads used in group SG

Countries

Germany

Contacts

Public ContactKarl Peter Rheinwalt

St. Franziskus-Hospital, Köln

karlpeter.rheinwalt@cellitinnen.de+4922155911050

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026